NEW YORK — Quotient Limited on Tuesday reported a 5 percent year-over-year increase in revenues for its fiscal fourth quarter on gains made by its Alba reagent business.
For the three-month period ended March 31, Quotient's revenues climbed to $8.7 million from $8.3 million the year before, bolstered by an 11 percent year-over-year rise in reagent revenues. The company's revenues in its Q4 2019 included a $450,000 milestone payment under a now-ended supply agreement with Ortho Clinical Diagnostics.